Waltham, Mass. and Tokyo, Japan — March 1, 2006 — Dynogen Pharmaceuticals, Inc. and Astellas Pharma, Inc. announced today that Astellas has acquired Dynogen's North Carolina-based research facility. Financial details regarding the sale were not disclosed. The research facility specializes in state-of-the-art preclinical studies for genitourinary disorders.

"We've built an impressive clinical and preclinical pipeline through our unique understanding of the neuroscience underlying gastrointestinal and genitourinary disorders, leveraging that knowledge to generate strong intellectual property and utilizing that intellectual property to enable an aggressive in-licensing program," said Lee R. Brettman, M.D., President and CEO of Dynogen. "We've maximized the value of the North Carolina facility in this effort, and now will focus all of our efforts on advancing the development of our five clinical programs and our late-stage preclinical programs."

"Dynogen has built a facility with first-class capabilities for evaluating the clinical potential of urological development candidates especially in the area of lower urinary tract disorders. The acquisition of this research facility will strengthen our capabilities in this key area," said Isao Yanagisawa, Ph.D., Senior Corporate Officer of Astellas Pharma, Inc.

About Dynogen Pharmaceuticals, Inc.
Dynogen is a privately held, neuroscience-based pharmaceutical company developing more effective treatments for gastrointestinal and genitourinary disorders. Today, Dynogen has three clinical development candidates, DDP200 for overactive bladder, DDP225 for irritable bowel syndrome with diarrhea (IBS-d) and chronic functional vomiting (CFV), and DDP733 for IBS with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (n-GERD). More information about the Company can be found by visiting our website www.dynogen.com.

About Astellas Pharma Inc.
Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. In April 2005, the company was formed through the merger of Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd. The organization is committed to becoming a global mega pharmaceutical company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. For more information on Astellas Pharma Inc., please visit the company's website at www.astellas.com.



Company Contact
Dynogen Pharmaceuticals, Inc.
Mark Boshar
[781] 839-5114
mboshar@dynogen.com

Company Contact
Astellas Pharma Inc.
Akihiro Tanaka, Ph.D., Vice President, Corporate Communications
+81-3-3244-3201

Media
MacDougall Biomedical Communications
Kari Watson
[508] 647-0209 ext. 11
kwatson@macbiocom.com